Company Profile

Genomic Vision is a molecular diagnostics and technology company specialized in the development of single DNA detection tools for research and in vitro diagnostics

 

 

News & Events

14/12/2015

 

Genomic Vision and Reims University Hospital Launch Clinical Study to Establish New Screening Tool for Early Detection and Prevention of Cervical Cancer  

The Largest Study ever Undertaken Using the Molecular Combing Technique on 3,500 Patients at 11 French Hospitals

 

 

Bagneux France (December 14, 2015) – Genomic Vision (GV: EN Paris), a molecular diagnostics company specializing in the development of diagnostic tests for genetic diseases and cancers based on molecular combing technology, today announces that it has signed a partnership agreement with the Reims University Hospital (CHU de Reims) for a clinical study aiming to validate the integration of the high-risk human papillomavirus (HPV-HR) as an appropriate indicator of the progression of cervical lesions towards cervical cancer. This prospective multicenter study, called IDAHO (Intégration de l’ADN des HPV Oncogènes, or integration of oncogenic HPV DNA), will involve 3,500 patients to be treated at 11 leading French gynecology hospitals.

 

HPV-HR DNA is the only independent risk factor for cervical cancer, which is the second most common form of cancer in women, behind breast cancer. Every year, almost 500,000 new cases and between 250,000 and 300,000 deaths are recorded worldwide. Due to its slow progression, cervical cancer can be prevented through screening and the treatment of precancerous lesions.

 

This study aims to validate the integration of HPV-HR DNA in patients’ genomes as an indicator of the severity of cervical lesions. This indicator will also help identify lesions presenting a high risk of developing cervical cancer. Genomic Vision’s molecular combing technique is currently the only one that allows direct and high-resolution visualization of the integration of high-risk HPV genomes, as shown by the data presented by the Company at the 29th International Papillomavirus Conference & Clinical Workshop in Seattle (see the press release of August 25, 2014).

 

Thus far, screening has been essentially based on cervical smears and tests to detect viral RNA or DNA (HPV tests). Cervical smears are not sensitive enough while HPV tests, which are highly sensitive, are not sufficiently specific. These tests result in unnecessary, invasive and expensive clinical examinations, as well as excessive treatments that can have detrimental effects on the future pregnancies of these women, who are often young.

 

The goal of the IDAHO study is to overcome this diagnostic insufficiency by identifying a biomarker that can specifically differentiate between women with a high risk of developing cervical cancer, and who therefore require treatment, and women with a low risk who require appropriate monitoring, explains Professor Olivier Graesslin, M.D., Head of the Reims University Hospital’s Gynecology-Obstetrics unit and coordinator of this study.

 

The IDAHO study will comprise two phases:

  • The first, cross-sectional phase, will involve the recruitment of 3,500 patients for 3 years beginning in December 2015 with an aim to show that the integration of HPV is a biomarker for diagnosing high-risk precancerous lesions that require immediate care and treatment.
  • The second phase will follow patients who have tested positive for HPV infection with low-grade precancerous lesions for three years, in order to confirm that the integration of HPV DNA is a biomarker for the progression of precancerous lesions.

 

Aaron Bensimon, Ph.D., Genomic Vision’s co-founder and Chairman, concludes: This clinical study involving 11 leading French hospitals is the largest one that Genomic Vision has participated in, and reflects the medical community’s need for the development of more efficient cervical cancer screening tests. The quality of this consortium’s partners makes us particularly optimistic regarding the outcome of our collaboration. Once it has been validated, our HPV test should increase the efficacy of the diagnosis and thus enable patients to be steered towards the most suitable treatment, therefore avoiding the need for unnecessary, invasive and expensive colposcopies.”

 


Upcoming financial publication

  • Annual Revenue for 2015, Monday, January 18, 2016* (after trading)

* indicative date, which may be subject to change

 


ABOUT THE REIMS UNIVERSITY HOSPITAL

In keeping with public service values, the Reims University Hospital (“Centre Hospitalier Universitaire de Reims”, or “CHU de Reims”) strives to meet one goal: to provide, through its 15 medical departments, excellent care and high-quality treatment to all patients in the Champagne-Ardenne region of France.

The Reims University Hospital also works hard to maintain its positioning as a university hospital and to promote the involvement of its medical staff in innovative research projects.

Professor Christine Clavel and Doctor Véronique Dalstein, molecular biologists in the Reims University Hospital’s Biopathology laboratory, have for many years been involved in research into HPV infections and use of the HPV test in clinical practice, notably in cervical cancer screening. This area of research is part of the Eastern France Cancer Research Cluster’s virus and cancer focus. Their research work in this field has received domestic and international acclaim.

For further information, please go to: www.chu-reims.fr

 

CONTACTS

Genomic Vision: Aaron Bensimon Co-founder, Chairman & CEO Tel.: +33 1 49 08 07 50 investisseurs@genomicvision.com

 

NewCap Investor Relations / Strategic Communications Dušan Orešanský / Emmanuel Huynh Tel.: +33 1 44 71 94 92 gv@newcap.eu

 

LHA: Investor Relations US: Anne Marie Fields, SVP Tel.: 212-838-3777 afields@lhai.com 

 

Reims University Hospital: Julie Collin, PR Manager Tel.: +33 3 26 78 34 38 jcollin@chu-reims.fr 

 

Member of CAC® Mid & Small, CAC® All-Tradable and EnterNext© PEA-PME 150 indexes

 

DISCLAIMER

This press release contains certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the prospectus on which the French Financial Market Authority (AMF) granted its visa n° 14-087 on March 19, 2014 and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements. This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for GENOMIC VISION shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.

 

 

news

 

genomic_web_visuels_footer_COMPANY